Bacopa and sleep: results of different extracts
What bacopa studies showed about sleep in adults with stress, sleep complaints and no sleep disturbances.
Key points
- In adults with recently developed stress, B-Lit improved sleep scores by 3.18 points more than placebo over 84 days. This is an average questionnaire result for a specific group and extract. [1] See the evidence 1
- In adults reporting poor sleep, questionnaire scores improved with both Bacognize and placebo; no additional extract advantage was found over 27 days. No difference was detected for this measure. [2] See the evidence 1
- In healthy adults without sleep disturbances, B-Lit improved sleep scores by an additional 1.65 points versus placebo over 84 days. This result does not describe people with sleep disturbances. [3] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Bacopa extracts were studied in different groups; sleep assessment and study durations differed.
Key points
Why these conclusions
Sleep results in different groups
Adults aged 18–60 with stress lasting no more than 12 weeks took B-Lit 300 mg per day or placebo for 84 days. Sleep-problem scores fell by 3.70 and 0.52 points, respectively. [1]
In physically healthy adults reporting poor sleep, Bacognize 150 mg twice daily was compared with placebo. By day 27, questionnaire measures improved in both groups, but no extract advantage was found. [2]
In a study of healthy adults without sleep disturbances, sleep scores over 84 days fell by 1.71 points with B-Lit and 0.06 with placebo. Certainty for each result is low, 2 out of 4. [3]
PSQI sleep-problem scores fell over 84 days by an average of 3.70 points with B-Lit and 0.52 with placebo; the difference in change was 3.18 points. A lower score means better sleep.
| Parameter | Data |
|---|---|
| Result | PSQI sleep-problem scores fell over 84 days by an average of 3.70 points with B-Lit and 0.52 with placebo; the difference in change was 3.18 points. A lower score means better sleep. |
| Participants | Adults aged 18–60 with stress lasting no more than 12 weeks and no psychiatric diagnosis: 50 allocated to groups, 44 completed (23 B-Lit, 21 placebo) |
| Form | B-Lit, capsule containing 300 mg extract standardized to 30% bacosides |
| Dose | 300 mg extract per day; one capsule in the morning after breakfast |
| Dose basis | 300 mg extract per day; one capsule in the morning after breakfast |
| Comparator | Placebo: capsule containing 500 mg microcrystalline cellulose |
| Duration | 84 days |
| Certainty | 2/4: Risk of error: Only study completers were analyzed; several participants dropped out. Many measures were tested. Repeatability: One trial is presented for this comparison; studies of other extracts do not replicate it. Applicability: The result concerns the specified extract, group and specific task. Precision: The sample was small; precision of the between-group difference is limited. Publication completeness: One trial is insufficient to assess whether negative results remained unpublished. |
| Volume of evidence | randomized study |
| Sources | [1] |
On the BIS insomnia questionnaire, scores fell from 27.77 to 13.89 points with Bacognize and from 28.18 to 14.98 with placebo by day 27. Sleep improved in both groups; no advantage of Bacognize was found.
| Parameter | Data |
|---|---|
| Result | On the BIS insomnia questionnaire, scores fell from 27.77 to 13.89 points with Bacognize and from 28.18 to 14.98 with placebo by day 27. Sleep improved in both groups; no advantage of Bacognize was found. |
| Participants | Physically healthy adults aged 18–70 with complaints of poor sleep: 100 allocated to groups, final questionnaires obtained from 89 (44 Bacognize, 45 placebo) |
| Form | Bacognize, hydroalcoholic whole-plant extract in capsules; 12% bacopa glycosides by HPLC |
| Dose | 150 mg extract twice daily, morning and evening, with or without food; 300 mg/day total |
| Dose basis | 150 mg extract twice daily, morning and evening, with or without food; 300 mg/day total |
| Comparator | Placebo: matching capsules containing microcrystalline cellulose |
| Duration | 28-day study; 27 days of use, final questionnaire on day 27 |
| Certainty | 2/4: Risk of error: Final questionnaires were missing for 11 of 100 participants. Emotional well-being was assessed as an additional outcome; the primary sleep measure showed no advantage. Repeatability: One trial is presented for this comparison; studies of other extracts do not replicate it. Applicability: The result concerns the specified extract, group and specific task. Precision: The sample was small; precision of the between-group difference is limited. Publication completeness: One trial is insufficient to assess whether negative results remained unpublished. |
| Volume of evidence | randomized study |
| Sources | [2] |
In adults without sleep disturbances, PSQI scores fell over 84 days by an average of 1.71 points with B-Lit and 0.06 with placebo; the difference in change was 1.65 points. A lower score means better sleep.
| Parameter | Data |
|---|---|
| Result | In adults without sleep disturbances, PSQI scores fell over 84 days by an average of 1.71 points with B-Lit and 0.06 with placebo; the difference in change was 1.65 points. A lower score means better sleep. |
| Participants | Healthy adults aged 18–55 without sleep disturbances: 80 allocated to groups, 74 completed the study (38 B-Lit, 36 placebo) |
| Form | B-Lit, capsule containing 300 mg extract and 90 mg bacosides |
| Dose | 300 mg extract per day; one capsule in the morning after breakfast |
| Dose basis | 300 mg extract per day; one capsule in the morning after breakfast |
| Comparator | Placebo: capsule containing microcrystalline cellulose |
| Duration | 84 days |
| Certainty | 2/4: Risk of error: Only study completers were analyzed; several participants dropped out. Many measures were tested. Repeatability: One trial is presented for this comparison; studies of other extracts do not replicate it. Applicability: People with sleep disturbances were not included. This result describes sleep scores in participants who were healthy at baseline. Precision: The sample was small; precision of the between-group difference is limited. Publication completeness: One trial is insufficient to assess whether negative results remained unpublished. |
| Volume of evidence | randomized study |
| Sources | [3] |
Information from the source
Nausea, abdominal pain, diarrhea, gas, headache, dizziness and rash have been described with bacopa use. In the Bacumen study, complaints, mainly digestive complaints and headache, occurred more often than with placebo; no serious adverse reactions were noted. Pregnant and breastfeeding women were excluded from the described B-Lit and Bacognize studies. These trials do not provide a basis for choosing a dose for them. Tolerability information here concerns the studied products and periods up to 12 weeks. [1] [4] [3] [2] [5]
Sources
- Efficacy and Safety of Bacopa monnieri Extract for Stress Management and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial. https://www.gavinpublishers.com/article/pdf/efficacy-and-safety-of-bacopa-monnieri-extract-for-stress-management-and-sleep-quality-a-randomized-doubleblind-placebocontrolled-trial
- Effects of a Bacopa monnieri extract (Bacognize®) on stress, fatigue, quality of life and sleep in adults with self-reported poor sleep: A randomised, double-blind, placebo-controlled study. https://www.sciencedirect.com/science/article/pii/S1756464621003200
- Effect of Bacopa monnieri Extract on Memory and Cognitive Skills in Adult Humans: A Randomized, Double-Blind, Placebo-Controlled Study. https://www.gavinpublishers.com/article/view/effect-of-bacopa-monnieri-extract-on-memory-and--cognitive-skills-in-adult-humans-a-randomized-double-blind-placebo-controlled-study
- The Effects of a Bacopa monnieri Extract (Bacumen®) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/41091332/
- Bacopa monnieri. https://www.ncbi.nlm.nih.gov/books/NBK603563/
Methodology: Subpages evidence-led supplement pipeline v1